biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
MRQ-36, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (119M-14), vial of 0.5 mL concentrate (119M-15), bottle of 1.0 mL predilute (119M-17), vial of 1.0 mL concentrate (119M-16), bottle of 7.0 mL predilute (119M-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
isotype
IgG1κ
control
tonsil
shipped in
wet ice
storage temp.
2-8°C
visualization
membranous
Gene Information
human ... CD19(930)
General description
CD19 is present in both normal and malignant B-cells and has long been considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, mantle zone cells, and scattered cells in the interfollicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in immature B-cells; although recent studies have described CD19 loss in a few B-cell neoplasms.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
 IVD |  IVD |  IVD |  RUO |
Other Notes
CD19 Positive Control Slides, Product No. 119S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
法规信息
监管及禁止进口产品
此项目有
Y K Onno Teng et al.
Arthritis and rheumatism, 56(12), 3909-3918 (2007-12-01)
Anti-CD20-mediated B cell depletion with rituximab is a new and effective therapy for rheumatoid arthritis (RA). Although B cells in peripheral blood (PB) are consistently depleted in all patients, the clinical effects are more heterogeneous, possibly related to differences in
Oliver M Steinmetz et al.
Transplantation, 84(7), 842-850 (2007-11-07)
Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently
Miho Kimura et al.
International journal of hematology, 85(1), 41-48 (2007-01-31)
To clarify the clinicopathologic significance of a loss of CD19 expression in diffuse large B-cell lymphoma (DLBCL), we evaluated CD19 expression immunohistochemically in frozen sections from 227 patients who had received diagnoses of DLBCL according to the World Health Organization
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 119M-14 | 0841683123842 |
| 119M-15 | 0841683123859 |
| 119M-16-RUO | 04061836549374 |
| 119M-17 | 0841683123873 |
| 119M-16 | 0841683123866 |
| 119M-18 | 0841683123880 |